Testing by NIL showed that the product does not meet quality specification requirements regarding contamination with particles visible to the naked eye; in 9 of 20 tested vials such particles were found. Potential effects: complications after intravenous infusion, embolism, inflammation, local or systemic reactions.
Download the app and stay informed
Get instant notifications about recalled products and protect your family.
Important Information
Do not use the product from any batch. Check the name and dosage form; return any packs held to a pharmacy or according to the marketing authorisation holder’s instructions. If the medicine has been a...
The Chief Pharmaceutical Inspector withdrew all batches of Levosimendan Kabi 2.5 mg/ml concentrate for solution for infusion from the Polish market and prohibited their placing on the market, granting...
If you feel unwell after consuming this product, contact your doctor or call the poison control center.
FAQ
Related